Dr. Sue Currie serves as Chief Operating Officer of Virion Therapeutics, LLC, where she and the Company continue to pursue a safe, convenient, accessible, and effective treatment for functional cure for chronic hepatitis B for the 300+ million persons affected by this disease. Virion’s platform technologies, and pipeline, offer a novel checkpoint modifier containing mechanism to help restore a patient’s own immune response against cancer and chronic infections. Virion’s Lead Clinical Program, VRON-0200, presented data, earlier this year (which was also simultaneously published in The Lancet), that demonstrated that a single, well tolerated intramuscular dose of VRON-0200 alone, in chronically HBV-infected patients, produced sustained and/or continued anti-HBV responses (e.g., viral declines (HBsAg)) in the majority of treated patients at 1-year (23/27; 85%), and in 11/12 (92%) patients, out to 2+ years post dosing. As a result of these promising data, a global Phase 2b study (“SPARK-B”) for HBV Functional Cure is in development and planned for later this year.
In addition to her current activities, Sue has 20+ years of strategic, clinical, and scientific leadership, not only within biotechnology and different pharm companies, but also in Veterans Health Administration, academic, correctional health, and community care settings. Additionally, Sue has authored numerous pivotal scientific publications in immuno-oncology, chronic HBV, and other infectious diseases and is a Biotech Leader in the field.